Search Results 371-380 of 35399 for prostate cancer
Share · Tweet . VID-20109920. Home; Mayo Gets FDA Approval for New Imaging Agent for Recurrent Prostate Cancer: Urology. There's still time!
Many of the current imaging tests we have for prostate cancer are problematic in their ability to distinguish cancerous from non-cancerous prostate tissue. This ...
AZD5305 Vs Placebo In Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents · Overview · Participation ...
Prostate cancer is one of the most common types of cancer in men. Usually prostate cancer grows slowly and initially remains confined to the prostate gland ...
“These findings have important implications for prostate cancer treatment, because SPOP mutation or elevated BET protein expression can now be used as ...
It also means that many may live for decades in survivorship of prostate cancers. The concept of survivorship is really critical in the prostate cancer area. Dr ...
If the first therapy to treat prostate cancer doesn't work, there are other options available — with one exception. ... According to Lonnie Fynskov, a Mayo Clinic ...
Learn about the risks and results of this procedure, which is used to deliver radiation therapy for prostate cancer.
"Men with castration-resistant prostate cancer have abysmal survival rates, typically living an average of two years once hormone therapies fail," says Manish ...
It targets small, well-defined areas and is used for prostate cancer that hasn't spread. In some cases, it may be used for benign prostatic hyperplasia (BPH).
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Hurry to 3X your gift’s impact on cancer research and care!